51
|
Kaida M, Morita-Hoshi Y, Wakeda T, Yamaki Y, Soeda A, Kondo S, Morizane C, Ueno H, Okusaka T, Heike Y. Phase I trial of gemcitabine and Wilms' tumor 1 peptide vaccine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
52
|
Nio K, Ueno H, Okusaka T, Morizane C, Hagihara A, Kondo S, Mayahara H, Ito Y. Chemoradiotherapy versus gemcitabine-based chemotherapy in patients with unresectable, locally advanced pancreatic cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14504] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
53
|
Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Sato Y, Inaba Y, Satake M, Arai Y. A phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) for advanced hepatocellular carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
54
|
Morizane C, Okusaka T, Ikeda M, Furuse J, Ohkawa S, Nakachi K, Suzuki E, Ueno M. 6594 Phase II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71315-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
55
|
Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Kojima Y, Hagihara A, Hiraoka N. 6623 Cisplatin plus etoposide as first-line chemotherapy for poorly- differentiated neuroendocrine carcinoma of the hepatobiliary and pancreatic region. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71344-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
56
|
Kojima Y, Ueno H, Okusaka T, Morizane C, Kondo S, Hagihara A, Iwasa S. Hepatocellular carcinoma presenting with lung metastasis: Clinical characteristics and prognostic factors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15604] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15604 Background: The efficacy of systemic chemotherapy for hepatocellular carcinoma (HCC) has been limited, but sorafenib has changed the strategy treating for metastatic HCC. The lung is one of the most common metastatic sites for HCC. Therefore, we focused on clinical features and prognostic factors of HCC patients (pts) with lung metastasis in this study. Methods: Between January 2000 and April 2008, 1,117 HCC pts were admitted into our division. During this period, extrahepatic metastasis was detected in 286 pts, and the initial metastatic site was lung in 130 pts. The relationships between the characteristics of these pts at the time of lung metastasis detection and prognosis were examined. Results: There were 107 males and 23 females. Median age was 64 years. The Child-Pugh classification was A in 84 pts, B in 32 pts. HCV Ab was positive in 57 pts, HBs Ag was positive in 46 pts, and both were negative in 27 pts. The median survival time of all pts was 298 days. Univariate analysis revealed 12 of the 20 variables evaluated to be significantly associated with survival time: number of lung metastasis, presence of intrahepatic HCC, maximum size of intrahepatic HCC, presence of tumor thrombus, AFP, PIVKA II, albumin, prothrombin time, ALP, presence of ascites, Child-Pugh classification, and previous history of hepatic resection. Multivariate analysis using the Cox proportional hazards model demonstrated a lower number (≤5) of lung metastases (p<0.0001), the absence of intrahepatic HCC (p=0.0002), and the absence of ascites (p=0.0339) to be independent favorable prognostic factors. Conclusions: These results may provide useful reference data for determining treatment strategies and planning further clinical trials involving HCC patients with lung metastasis. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Kojima
- National Cancer Center Hospital, Tokyo, Japan
| | - H. Ueno
- National Cancer Center Hospital, Tokyo, Japan
| | - T. Okusaka
- National Cancer Center Hospital, Tokyo, Japan
| | - C. Morizane
- National Cancer Center Hospital, Tokyo, Japan
| | - S. Kondo
- National Cancer Center Hospital, Tokyo, Japan
| | - A. Hagihara
- National Cancer Center Hospital, Tokyo, Japan
| | - S. Iwasa
- National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
57
|
Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer 2009; 100:870-3. [PMID: 19293806 PMCID: PMC2661788 DOI: 10.1038/sj.bjc.6604971] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Among 242 Japanese pancreatic cancer patients, three patients (1.2%) encountered life-threatening toxicities, including myelosuppression, after gemcitabine-based chemotherapies. Two of them carried homozygous CDA*3 (CDA208G>A [Ala70Thr]), and showed extremely low plasma cytidine deaminase activity and gemcitabine clearance. Our results suggest that homozygous *3 is a major factor causing gemcitabine-mediated severe adverse reactions among the Japanese population.
Collapse
Affiliation(s)
- H Ueno
- Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
58
|
Okusaka T, Kanai F, Ikeda M, Morizane C, Yoshida H, Tateishi R, Shiina S, Kondo Y, Tagawa K, Omata M. 43 POSTER Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase (RTK) inhibitor, TSU-68, in the Phase I/II study for advanced hepatocellular carcinoma (HCC). EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71975-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
59
|
Furuse J, Ikeda M, Okusaka T, Nakachi K, Morizane C, Ueno H, Yamaura H, Inaba Y, Satake M, Arai Y. A phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
60
|
Furuse J, Okusaka T, Ishii H, Nakachi K, Suzuki E, Shimizu S, Ueno H, Ikeda M, Morizane C, Ogura T. 3553 POSTER Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of phase I part – Correlation between pharmacokinetics (PK) and hepatic dysfunction. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71056-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
61
|
Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, Shimada Y, Nakahama H, Matsumura Y. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 2007; 97:170-6. [PMID: 17595665 PMCID: PMC2360299 DOI: 10.1038/sj.bjc.6603855] [Citation(s) in RCA: 177] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusion every 3 weeks, without antiallergic premedication. The starting dose was 10 mg m−2, and the dose was escalated according to the accelerated titration method. Nineteen patients were recruited. The tumour types treated included pancreatic (n=11), bile duct (n=5), gastric (n=2), and colonic (n=1) cancers. Neutropenia was the most common haematological toxicity. A grade 3 fever developed in one patient given 180 mg m−2. No other grades 3 or 4 nonhaematological toxicities, including neuropathy, was observed during the entire study period. DLTs occurred in two patients given 180 mg m−2 (grade 4 neutropenia lasting for more than 5 days). Thus, this dose was designated as the MTD. Grade 2 hypersensitivity reactions developed in only one patient given 180 mg m−2. A partial response was observed in one patient with pancreatic cancer. The maximum concentration (Cmax) and area under the concentration (AUC) of NK105 were dose dependent. The plasma AUC of NK105 at 150 mg m−2 was approximately 15-fold higher than that of the conventional PTX formulation. NK105 was well tolerated, and the RD for the phase II study was determined to be 150 mg m−2 every 3 weeks. The results of this phase I study warrant further clinical evaluation.
Collapse
Affiliation(s)
- T Hamaguchi
- Department of Medicine National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
62
|
Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse J, Ishii H, Kawashima M, Kagami Y, Ikeda H. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer 2007; 96:1650-5. [PMID: 17533388 PMCID: PMC2359907 DOI: 10.1038/sj.bjc.6603788] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
This study investigated the maximum tolerated dose of S-1 based on the frequency of its dose-limiting toxicities (DLT) with concurrent radiotherapy in patients with locally advanced pancreatic cancer. S-1 was administered orally at escalating doses from 50 to 80 mg m−2 b.i.d. on the day of irradiation during radiotherapy. Radiation therapy was delivered through four fields as a total dose of 50.4 Gy in 28 fractions over 5.5 weeks, and no prophylactic nodal irradiation was given. Twenty-one patients (50 three; 60 five; 70 six; 80 mg m−2 seven patients) were enrolled in this trial. At a dose of 70 mg m−2 S-1, two of six patients demonstrated DLT involving grade 3 nausea and vomiting and grade 3 haemorrhagic gastritis, whereas no patients at doses other than 70 mg m−2 demonstrated any sign of DLT. Among the 21 enrolled patients, four (19.0%) showed a partial response. The median progression-free survival time and median survival time for the patients overall were 8.9 and 11.0 months, respectively. The recommended dose of S-1 therapy with concurrent radiotherapy is 80 mg m−2 day−1. A multi-institutional phase II trial of this regimen in patients with locally advanced pancreatic cancer is now underway.
Collapse
Affiliation(s)
- M Ikeda
- Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
63
|
Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Najima M, Hirokawa S, Nakachi K, Ogura T. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4115] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4115 Background: Gemcitabine (Gem) monotherapy or Gem-containing chemotherapy is the standard first line therapy for advanced pancreatic cancer. After disease progression, there is no standard regimen available. In a previous phase II trial (J. Furuse et al, Proc ASCO 2005: # 4104), S-1 has been reported to show considerable efficacy, achieving a response rate of 37.5% in chemo-naïve patients with pancreatic cancer. This study evaluated the efficacy and toxicity of S-1 in patients with Gem-refractory metastatic pancreatic cancer. Methods: Eligibility criteria were pathologically-proven pancreatic cancer with confirmation of progressive disease while receiving Gem-based chemotherapy, Karnofsky performance status 80 to 100%, age 20 to 74 years, with measurable metastatic lesions, adequate hematological, renal and liver functions, and written informed consent. S-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 14 days as one course. Administration was repeated until the appearance of disease progression or unacceptable toxicity. The primary study end point was objective response, secondary end points included toxicity, progression-free survival (PFS) and overall survival, as well as clinical benefit response in symptomatic patients. Results: Forty patients (pts) from two institutions were enrolled between September 2004 and November 2005. Thirty-three pts are currently evaluable for response in this ongoing trial. There have been 5 confirmed partial responses (12.5%), and 14 pts (35%) with stable disease. Median survival has not been reached. Median PFS was 2.1 months. Toxicity data were available for 28 patients. Grade 3 and 4 toxicities were anemia (1 pts), appetite loss (2 pts), and fatigue (2 pts). Conclusions: Preliminary results demonstrated the safety and activity of S-1 in Gem-refractory metastatic pancreatic cancer. Efficacy and toxicity analysis are ongoing. Final results will be presented at the meeting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Morizane
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - T. Okusaka
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - J. Furuse
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - H. Ishii
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - H. Ueno
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - M. Ikeda
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - M. Najima
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - S. Hirokawa
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - K. Nakachi
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - T. Ogura
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| |
Collapse
|
64
|
Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse J, Ishii H, Kawashima M, Kagami Y, Ikeda H. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14003 Background: S-1 is a novel oral fluoropyrimidine derivative, and a phase II trial of this agent has demonstrated promising results with a response rate of 37.5% and a median survival of 8.8 months with a mild toxicity profile for patients with metastatic pancreatic cancer. This study investigated the maximum tolerated dose of S-1 based on the frequency of dose-limiting toxicities (DLT) of S-1 with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Patients and Methods: Patients with locally advanced pancreatic cancer in whom adenocarcinoma had been confirmed histologically or cytologically were enrolled in this study. S-1 was administered orally in escalating doses from 50 mg/m2, which is reported to be equivalent to 200 mg/m2 intravenous 5-fluorouracil, to 80 mg/m2 bid in 10 mg/m2 increments on the day of irradiation (Monday through Friday) during radiotherapy. Radiation therapy was delivered through four fields as a total dose of 50.4 Gy in 28 fractions over 5.5 weeks. DLT was defined as grade 4 hematological toxicity and grade 3 or 4 non-hematological toxicity during chemoradiotherapy. The maximum tolerated dose was defined when three or more patients in a cohort of six patients experienced DLT. Results: Twenty-one patients (50 mg/m2 3 patients; 60 mg/m2 5 patients; 70 mg/m2 6 patients; 80 mg/m2 7 patients) were enrolled in this trial between May 2004 and November 2005. At 70 mg/m2 S-1, two of six patients demonstrated DLT involving grade 3 nausea and vomiting and grade 3 hemorrhagic gastritis, while all patients at dose levels other than 70 mg/m2 did not demonstrate any sign of dose-limiting toxicity. Of all 21 patients enrolled, 4 (19.0%) showed a partial response. More than a 50% reduction in the serum level of carbohydrate antigen 19–9 was observed in 12 (75%) of 16 patients in whom the pretreatment level was 100 U/ml or greater. Conclusion: The recommended dose of S-1 with concurrent radiotherapy is 80 mg/m2. This regimen may offer an easy alternative to intravenous 5-fluorouracil, and may be a promising treatment for locally advanced pancreatic cancer. A multicenter phase II trial of this regimen in patients with locally advanced pancreatic cancer is now underway. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Ikeda
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - T. Okusaka
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - Y. Ito
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - H. Ueno
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - C. Morizane
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - J. Furuse
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - H. Ishii
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - M. Kawashima
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - Y. Kagami
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| | - H. Ikeda
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan
| |
Collapse
|
65
|
Okusaka T, Ueno H, Ikeda M, Morizane C, Ishiguro Y, Kosuge T, Shimada K, Sano T, Sakamoto Y. A phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - H. Ueno
- National Cancer Ctr Hosp, Tokyo, Japan
| | - M. Ikeda
- National Cancer Ctr Hosp, Tokyo, Japan
| | | | | | - T. Kosuge
- National Cancer Ctr Hosp, Tokyo, Japan
| | | | - T. Sano
- National Cancer Ctr Hosp, Tokyo, Japan
| | | |
Collapse
|
66
|
Ikeda M, Ueno H, Okusaka T, Morizane C, Ito Y, Kagami Y, Ikeda H. Phase II study of hyperfractionated radiotherapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Ikeda
- National Cancer Ctr Hosp, Tokyo, Japan
| | - H. Ueno
- National Cancer Ctr Hosp, Tokyo, Japan
| | | | | | - Y. Ito
- National Cancer Ctr Hosp, Tokyo, Japan
| | - Y. Kagami
- National Cancer Ctr Hosp, Tokyo, Japan
| | - H. Ikeda
- National Cancer Ctr Hosp, Tokyo, Japan
| |
Collapse
|
67
|
Abstract
The aim of this study was to investigate the efficacy and safety of an oral fluoropyrimidine derivative, S-1, in patients with advanced biliary tract cancer. Patients with pathologically confirmed advanced biliary tract cancer, a measurable lesion, and no history of radiotherapy or chemotherapy were enrolled. S-1 was administered orally (40 mg m(-2) b.i.d.) for 28 days, followed by a 14-day rest period. A pharmacokinetic study was performed on day 1 in the initial eight patients. In all, 19 consecutive eligible patients were enrolled in the study between July 2000 and January 2002. The site of the primary tumour was the gallbladder (n=16), the extrahepatic bile ducts (n=2), and the ampulla of Vater (n=1). A median of two courses of treatment (range, 1-12) was administered. Four patients achieved a partial response, giving an overall response rate of 21.1%. The median time-to-progression and median overall survival period were 3.7 and 8.3 months, respectively. Although grade 3 anorexia and fatigue occurred in two patients each (10.5%), no grade 4 toxicities were observed. The pharmacokinetic parameters after a single oral administration of S-1 were similar to those of patients with other cancers. S-1 exhibits definite antitumour activity and is well tolerated in patients with advanced biliary tract cancer.
Collapse
Affiliation(s)
- H Ueno
- Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | | | |
Collapse
|
68
|
Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004; 91:673-7. [PMID: 15226765 PMCID: PMC2364779 DOI: 10.1038/sj.bjc.6602001] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Gemcitabine has been reported to be a potent radiosensitiser in human pancreatic cell lines. This study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. In all, 42 patients with pancreatic cancer that was unresectable but confined to the pancreatic region were treated with external-beam radiation (50.4 Gy in 28 fractions over 5.5 weeks) and weekly gemcitabine (250 mg m−2, 30-min infusion). Maintenance gemcitabine (1000 mg m−2 weekly × 3 every 4 weeks) was initiated 1 month after the completion of the chemoradiotherapy and continued until disease progression or unacceptable toxicity. Of the 42 patients, 38 (90%) completed the scheduled course of chemoradiotherapy. The major toxicity was leucopenia and anorexia. There was one death attributed to duodenal bleeding and sepsis. The median survival time was 9.5 months and the 1-year survival rate was 28%. The median progression-free survival time was 4.4 months. In 35 patients with documented disease progression at the time of analysis, 34 (97%) showed distant metastasis as the cause of the initial disease progression. The chemoradiotherapy used in this study has a moderate activity against locally advanced pancreatic cancer and an acceptable toxicity profile. Future investigations for treatment with more systemic effects are warranted.
Collapse
Affiliation(s)
- T Okusaka
- Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
69
|
Morizane C, Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Sumi M, Kagami Y, Ikeda H. Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Morizane
- National Cancer Center Hospital, Tokyo, Japan
| | - T. Okusaka
- National Cancer Center Hospital, Tokyo, Japan
| | - Y. Ito
- National Cancer Center Hospital, Tokyo, Japan
| | - H. Ueno
- National Cancer Center Hospital, Tokyo, Japan
| | - M. Ikeda
- National Cancer Center Hospital, Tokyo, Japan
| | - Y. Takezako
- National Cancer Center Hospital, Tokyo, Japan
| | - M. Sumi
- National Cancer Center Hospital, Tokyo, Japan
| | - Y. Kagami
- National Cancer Center Hospital, Tokyo, Japan
| | - H. Ikeda
- National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
70
|
Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous-infusion 5-fluorouracil, mitoxantone and cisplatin for metastatic hepatocellular carcinoma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Ikeda
- National Cancer Center Hospital, Tokyo, Japan
| | - T. Okusaka
- National Cancer Center Hospital, Tokyo, Japan
| | - H. Ueno
- National Cancer Center Hospital, Tokyo, Japan
| | - Y. Takezako
- National Cancer Center Hospital, Tokyo, Japan
| | - C. Morizane
- National Cancer Center Hospital, Tokyo, Japan
| |
Collapse
|
71
|
Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C, Furuse J, Ishii H, Nagase M. Phase I study of gemcitabine and S-1 combination therapy in patients with advanced pancreatic cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Ueno
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - T. Okusaka
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - M. Ikeda
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - Y. Takezako
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - C. Morizane
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - J. Furuse
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - H. Ishii
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| | - M. Nagase
- National Cancer Center Hospital, Tokyo, Japan; National Cancer Center Hospital East, Kashiwa, Japan
| |
Collapse
|
72
|
Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. 196 The efficacy, toxicity and pharmacokinetic findings of S-1 in patients (pts) with advanced biliary tract cancer (BTC): a phase II trial. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90229-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
73
|
Wu JZ, Wen YP, Ruan HL, Yao NH, Zhao QS, Sun HD, Morizane C, Iida A, Fujita T. Structural elucidations of two ent-kaurane dimers from bulbs of Fritillaria ebeiensis var. purpurea. J Asian Nat Prod Res 2000; 2:213-218. [PMID: 11256695 DOI: 10.1080/10286020008039913] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
A novel ent-kaurane diterpenoid dimer, fritillebinide B (1) together with one known diterpenoid dimer fritillebinide A (2) were isolated from the bulbs of Fritillaria eheiensis var. purpurea G.D. Yu et P. Li. Compound 1 has been established to be ent-3beta-acetoxy-kauran-16beta,17-acetal ent-16beta-kauran-17(R)-aldehyde (1) by means of spectral analysis and chemical evidence.
Collapse
Affiliation(s)
- J Z Wu
- Faculty of Pharmaceutical Sciences, Tongji Medical University, Wuhan, China
| | | | | | | | | | | | | | | | | |
Collapse
|
74
|
Wu JZ, Ruan HL, Yao NH, Zhao QS, Sun HD, Morizane C, Iida A, Fujita T. Structures of two diterpenoid dimers from bulbs of Fritillaria ebeiensis. J Asian Nat Prod Res 2000; 2:161-167. [PMID: 11256689 DOI: 10.1080/10286020008039907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
A new ent-kaurane diterpenoid dimer, fritillebinide C(1) together with one known diterpenoid dimer fritillebinide B (2) were isolated from the bulbs of Fritillaria ebeiensis G.D. Yu et G.Q. Ji. Compound 1 has been determined to be ent-3beta-acetoxy-kauran-16beta,17-acetal ent-16beta-kauran-17(S)-aldehyde(1) by means of spectral analysis and chemical evidence.
Collapse
Affiliation(s)
- J Z Wu
- Faculty of Pharmaceutical Sciences, Tongji Medical University, Wuhan, Hubei Province, China
| | | | | | | | | | | | | | | |
Collapse
|
75
|
Adachi K, Kashii S, Masai H, Ueda M, Morizane C, Kaneda K, Kume T, Akaike A, Honda Y. Mechanism of the pathogenesis of glutamate neurotoxicity in retinal ischemia. Graefes Arch Clin Exp Ophthalmol 1998; 236:766-74. [PMID: 9801892 DOI: 10.1007/s004170050156] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
PURPOSE This study was carried out to examine the involvement of glutamate and nitric oxide neurotoxicity in ischemia/reperfusion-induced retinal injury in vivo. METHODS We monitored glutamate release from in vivo cat retina during and after pressure-induced ischemia using a microdialysis technique. Morphometric studies were performed to study the effects of MK-801 (dizocilpine), L-NAME (N omega-nitro-L-arginine methyl ester), and D-NAME (N omega-nitro-D-arginine methyl ester) on the histological changes in the rat retina induced by ischemia or intravitreal injection of NMDA (N-methyl-D-aspartate; 200 nmol). RESULTS A large release of glutamate occurred during ischemia, followed by a marked release after reperfusion. Histological changes occurred selectively in the inner part of the retina after ischemia as well as intravitreal injection of NMDA. Pretreatment with intravenous injection of MK-801 or L-NAME significantly inhibited the ischemic injury of the inner retina. Intravitreal injection of L-NAME inhibited NMDA-induced neurotoxicity in the retina. CONCLUSION These findings indicate that nitric oxide mediates neurotoxic actions of glutamate which are responsible for ischemic injury in the retina.
Collapse
Affiliation(s)
- K Adachi
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Adachi K, Fujita Y, Morizane C, Akaike A, Ueda M, Satoh M, Masai H, Kashii S, Honda Y. Inhibition of NMDA receptors and nitric oxide synthase reduces ischemic injury of the retina. Eur J Pharmacol 1998; 350:53-7. [PMID: 9683014 DOI: 10.1016/s0014-2999(98)00317-3] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
This study was performed to examine the roles of body temperature, NMDA receptors and nitric oxide (NO) synthase in post-ischemic retinal injury in rats. Cell loss in the ganglion cell layer and thinning of the inner plexiform layer were observed 7 days after ischemia. Cell loss in the ganglion cell layer but not thinning of the inner plexiform layer was reduced by hypothermia during ischemia. Intravenous injection of dizocilpine (MK-801) or Nomega-nitro-L-arginine methyl ester (L-NAME) prior to ischemia ameliorated retinal injury. These results suggest that activation of NO synthase following NMDA receptor stimulation is involved in ischemia-induced retinal injury.
Collapse
Affiliation(s)
- K Adachi
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
77
|
Morizane C, Adachi K, Furutani I, Fujita Y, Akaike A, Kashii S, Honda Y. N(omega)-nitro-L-arginine methyl ester protects retinal neurons against N-methyl-D-aspartate-induced neurotoxicity in vivo. Eur J Pharmacol 1997; 328:45-9. [PMID: 9203567 DOI: 10.1016/s0014-2999(97)83026-9] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
We investigated whether the inhibition of nitric oxide (NO) synthesis with N(omega)-nitro-L-arginine methyl ester (L-NAME), a competitive inhibitor of NO synthase, affects N-methyl-D-aspartate (NMDA)-induced neurotoxicity in the rat retina in vivo. A single intravitreal injection of NMDA damaged the ganglion cell layer and the inner plexiform layer without affecting the other retinal layers 7 days after injection. Intravitreal injection of (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5, 10-imine hydrogen maleate (MK-801) with NMDA significantly reduced NMDA-induced degeneration of the retina. NMDA-induced degeneration was also prevented by intravitreal injection of L-NAME but not of D-NAME. The protective effect of L-NAME was antagonized by L-arginine. These results suggest that NO plays an important role in NMDA-induced excitotoxic degeneration in the retina.
Collapse
Affiliation(s)
- C Morizane
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, Japan
| | | | | | | | | | | | | |
Collapse
|